Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. In Memoriam: Arvid Carlsson-Pioneering Researcher and Nobel Laureate

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Interactive effects between hemizygous 15q13.3 microdeletion and peripubertal stress on adult behavioral functions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Startle habituation, sensory, and sensorimotor gating in trauma-affected refugees with posttraumatic stress disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The impact of schizophrenia and intelligence on the relationship between age and brain volume

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Schizophrenia is a complex brain disease involving several neurotransmitter systems, including aberrant noradrenergic activity, which might underlie cognitive deficits. Clonidine is an α2A-agonist and previous research has demonstrated that single dosages of clonidine normalize sensori(motor) gating in schizophrenia. Currently, we investigated whether clonidine is able to normalize mismatch negativity (MMN) and P3a amplitude deficits in this same group of patients. This is important, since reports have shown that MMN amplitude is associated with cognitive functioning and daily life functions in schizophrenia. Twenty chronically ill, male schizophrenia patients were tested with the MMN paradigm from the Copenhagen Psychophysiological Test Battery (CPTB) on 5 occasions, separated by a week. Patients received randomized, yet balanced, either a placebo or a single dose (25, 50, 75 or 150 μg) of clonidine (each dose only once) on top of their usual medication on each occasion. Patients were matched on age and gender with 20 healthy controls (HC) who did not receive any treatment. We found decreased MMN and P3a amplitudes in our patients compared to HC. Although clonidine did neither significantly increase MMN nor P3a amplitude in our patients, it did increase certain levels of MMN and P3a amplitude such that these were not significantly different anymore from the healthy controls. Together with our previous reports indicating normalized sensori(motor) gating in the same patients following administration of clonidine, our results could be of potential high clinical relevance in treating schizophrenia. Future studies should focus on longer trial periods to investigate if clonidine also improves cognitive functioning in schizophrenia.

OriginalsprogEngelsk
Artikelnummer6
TidsskriftNeuropsychopharmacology
Vol/bind44
Udgave nummer6
Sider (fra-til)1062-1067
Antal sider6
ISSN0893-133X
DOI
StatusUdgivet - maj 2019

ID: 56725270